Calls
1
Richard Francis
CEO, Teva Pharmaceutical
Win Rate
100.0%
return
+20.8%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 13
$32.06
+20.8%
Teva is transforming from a pure generics company to a biopharma company; branded/innovation sales should outpace generics by 2030 and the late-stage pipeline could generate nearly $12B by 2035. Existing innovative products are growing over 30%, multiple 2026 data readouts and launches are coming, and the long-acting olanzapine schizophrenia franchise could launch around late Q3/early Q4.
Pharma & Biotech
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Richard Francis has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: TEVA.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
